SEARCH:   Advanced

Blood, 1 June 2007, Vol. 109, No. 11, pp. 4930-4935. Prepublished online as a Blood First Edition Paper on February 13, 2007; DOI 10.1182/blood-2006-09-047068. This Article Full Text Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2006-09-047068v1 109/11/4930    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nyman, H. Articles by Leppä, S. Search for Related Content PubMed PubMed Citation Articles by Nyman, H. Articles by Leppä, S. Related Collections Immunotherapy Clinical Trials and Observations Immunobiology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Heidi Nyman1,2, Magdalena Adde3, Marja-Liisa Karjalainen-Lindsberg4, Minna Taskinen1,2, Mattias Berglund3, Rose-Marie Amini5, Carl Blomqvist1,3, Gunilla Enblad3, and Sirpa Leppä1,2 1 Department of Oncology, Helsinki University Central Hospital, Finland; 2 Molecular Cancer Biology Research Program, Biomedicum Helsinki, University of Helsinki, Finland; 3 Department of Oncology, Uppsala University Hospital, Sweden; 4 Department of Pathology, Haartman Institute, University of Helsinki, Finland; 5 Department of Genetics and Pathology, University of Uppsala, Sweden Germinal center (GC) and non-GC phenotypes are predictors of outcome in diffuse large B-cell lymphoma (DLBCL) and can be used to stratify chemotherapy-treated patients into low- and high-risk groups. To determine how combination of rituximab with chemotherapy influences GC-associated clinical outcome, GC and non-GC phenotypes were identified immunohistochemically from samples of 90 de novo DLBCL patients treated with rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)–like regimen (immunochemotherapy). One hundred and four patients previously treated with chemotherapy served as a control group. Consistent with previous studies, chemotherapy-treated patients with immunohistochemically defined GC phenotype displayed a significantly better overall (OS) and failure-free survival (FFS) than the non-GC group (OS, 70% vs 47%, P = .012; FFS, 59% vs 30%, P = .001). In contrast, immunohistochemically defined GC phenotype did not predict outcome in immunochemotherapy-treated patients (OS, 77% vs 76%, P = ns; FFS, 68% vs 63%, P = ns). In comparison, International Prognostic Index (IPI) could separate the high-risk patients from low- and intermediate-risk groups (OS, 84% vs 63%, P = .030; FFS, 79% vs 52%, P = .028). We conclude that rituximab in combination with chemotherapy seems to eliminate the prognostic value of immunohistochemically defined GC- and non-GC phenotypes in DLBCL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Shimada, K. Matsue, K. Yamamoto, T. Murase, N. Ichikawa, M. Okamoto, N. Niitsu, H. Kosugi, N. Tsukamoto, H. Miwa, et al. Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan J. Clin. Oncol., July 1, 2008; 26(19): 3189 - 3195. [Abstract] [Full Text] [PDF] D. Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy Ann. Onc., June 23, 2008; (2008) mdn392v1. [Abstract] [Full Text] [PDF] W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al. Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers J. Clin. Oncol., June 1, 2008; 26(16): 2717 - 2724. [Abstract] [Full Text] [PDF] S. Nakamura, H. Ye, C. M. Bacon, A. Goatly, H. Liu, L. Kerr, A. H. Banham, B. Streubel, T. Yao, M. Tsuneyoshi, et al. Translocations Involving the Immunoglobulin Heavy Chain Gene Locus Predict Better Survival in Gastric Diffuse Large B-Cell Lymphoma Clin. Cancer Res., May 15, 2008; 14(10): 3002 - 3010. [Abstract] [Full Text] [PDF] D. O. Persky, J. M. Unger, C. M. Spier, B. Stea, M. LeBlanc, M. J. McCarty, L. M. Rimsza, R. I. Fisher, and T. P. Miller Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014 J. Clin. Oncol., May 10, 2008; 26(14): 2258 - 2263. [Abstract] [Full Text] [PDF] M. A. Shipp Molecular Signatures Define New Rational Treatment Targets in Large B-Cell Lymphomas Hematology, January 1, 2007; 2007(1): 265 - 269. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020